<DOC>
	<DOC>NCT00895882</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and efficacy of vaniprevir when administered concomitantly with pegylated interferon (peg-IFN) and ribavirin (RBV) to treat treatment-naive genotype 1 hepatitis C virus (HCV)-infected patients.</brief_summary>
	<brief_title>Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patient has chronic genotype 1 HCV infection Patient has had a liver biopsy without evidence of cirrhosis Patient has had an eye exam prior to the start of study Female patients capable of having children and male patients with female partners capable of having children agree to use two forms of birth control throughout the study Patient has had previous treatment with: 3 or more doses IFN, pegIFN, and/or RBV; and stopped treatment due to intolerance of one of the drugs; other antiviral or investigational therapies or vaccines for HCV Female patient is pregnant or breastfeeding Patient has chronic hepatitis not caused by HCV Patient has evidence of cirrhosis of the liver Patient has HIV Patient has active hepatitis B infection Patient has nongenotype 1 HCV infection Patient consumes excessive amounts of alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>